Singapore Steps Up Enforcement and Crackdown on E-Cigarettes

Regulations by 2FIRSTS.ai
Dec.20.2023
Singapore Steps Up Enforcement and Crackdown on E-Cigarettes
Singapore's health ministry aims to crack down on the sale and use of e-cigarettes, despite a ban, by ramping up enforcement efforts.

According to a report by Singapore's Lianhe Zaobao on December 19, the Singapore Ministry of Health has pointed out that despite the ban on the sale and use of e-cigarettes in the country, there are still avenues for the public to purchase them. In response to this situation, the Ministry of Health plans to intensify joint enforcement efforts and raising public awareness to combat the circulation of e-cigarettes.

 

In a joint statement issued on December 19th last year, the Ministry of Health and the Health Science Bureau announced their findings that the public can still obtain e-cigarettes through chatting applications such as Telegram or while traveling abroad. In an effort to prevent further deterioration of the e-cigarette issue in the country, the Ministry of Health, along with other government agencies, intends to strengthen enforcement measures and awareness campaigns regarding e-cigarettes.

 

In recent times, the Health Sciences Authority (HSA) has announced a joint operation with the Immigration and Checkpoints Authority (ICA) to carry out enforcement measures at ports, land checkpoints, and airports, starting from Changi Airport. The primary objective of this operation is to crack down on incoming passengers carrying e-cigarettes, with violators being subject to fines. The HSA will also collaborate with the Ministry of Communications and Information and the Infocomm Media Development Authority to enhance the monitoring and prohibition of e-cigarette online sales and advertising.

 

In addition, the Ministry of Health, in collaboration with the Ministry of Education, the National Environmental Agency, the National Parks Board, and the Singapore Police Force, has ramped up enforcement efforts regarding the possession and use of e-cigarettes. Since December 1st of last year, enforcement officers from the Environmental Agency have been authorized to take action against individuals found using or possessing e-cigarettes, with some cases being passed on to the Health Sciences Authority for further investigation.

 

Inspections at public places such as central business districts, shopping centers, parks, smoking areas, bars, and clubs will also be intensified, with violators facing on-the-spot fines. In schools, if students are found using or in possession of e-cigarettes, the school authorities will confiscate the e-cigarette, inform parents, and report the incident to the Department of Health, to ensure strict punishment for such violations.

 

According to the latest data released by the Health Science Bureau, from 2018 to 2022, a total of 860 individuals have been involved in the sale and smuggling of e-cigarettes and their accessories, with 145 of them being brought to court. Last year, the number of arrests for using and possessing e-cigarettes reached 4,916, nearly triple the figure from 2020. In the period from April to August this year, 18 individuals were sentenced for selling e-cigarettes and their accessories.

 

According to Minister Wong Yi Kang's response to written queries in Parliament last November, approximately 20% of the individuals arrested for purchasing or possessing e-cigarettes in the first nine months of last year were under the age of 18.

 

According to tobacco regulations, the import, distribution, or sale of e-cigarettes is considered illegal. First-time offenders can face a maximum fine of SGD 10,000 or six months of imprisonment, or both. Repeat offenders can be fined SGD 20,000, imprisoned for one year, or both. Individuals found in possession of, using, or purchasing e-cigarettes may face a maximum fine of SGD 2,000.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

U.S. Health Groups Seek to Overturn FDA Enforcement Discretion for Pending PMTAs as Altria's Helix, NJOY and AVM Move to Intervene
U.S. Health Groups Seek to Overturn FDA Enforcement Discretion for Pending PMTAs as Altria's Helix, NJOY and AVM Move to Intervene
American Vapor Manufacturers (AVM) and Altria subsidiaries Helix Innovations and NJOY filed separate motions on October 7, 2026, seeking to intervene on the FDA's side in a lawsuit challenging its enforcement guidance for certain e-cigarette and nicotine pouch products with pending premarket tobacco product applications (PMTAs). Seven public health and tobacco-control organizations, including the Campaign for Tobacco-Free Kids, sued the agency in July to overturn the policy. AVM argues that vacating the guidance could disrupt orders, inventory, retail distribution and investments in regulatory submissions.
Regulations
Oct.09
FRE and ALP Push Modern Oral to 48% of Q2 Sales as Turning Point Brands Changes CEO and Lowers Profit-Guidance Ceiling
FRE and ALP Push Modern Oral to 48% of Q2 Sales as Turning Point Brands Changes CEO and Lowers Profit-Guidance Ceiling
Turning Point Brands said Executive Chairman David E. Glazek will become CEO on October 1, replacing Graham Purdy, who is stepping down for personal reasons. The company narrowed its 2026 adjusted EBITDA outlook to $70 million-$80 million from $70 million-$90 million while maintaining Modern Oral gross sales guidance of $330 million-$350 million and net sales guidance of $260 million-$270 million. In the second quarter, Modern Oral net sales rose 128% to $68.4 million and accounted for 48% of company-wide net sales. Adjusted EBITDA fell 50% year over year. TPB shares closed about 10% lower on September 21.
Market
Sep.22 by 2Firsts Perspectives
As JUUL2 Wins FDA Authorization, Harm Reduction Journal Highlights the Role of Real-World Evidence in Nicotine Product Regulation
As JUUL2 Wins FDA Authorization, Harm Reduction Journal Highlights the Role of Real-World Evidence in Nicotine Product Regulation
A commentary published in the international open-access, peer-reviewed Harm Reduction Journal argues that randomized controlled trials remain central to evaluating smoking cessation efficacy but cannot alone capture real-world uptake, complete switching, longer-term use and population impact of non-combustible nicotine products such as e-cigarettes, heated tobacco and nicotine pouches. The authors frame impact as “reach × efficacy” and call for real-world evidence to complement RCTs. Three days after publication, the FDA authorized three JUUL2 products and highlighted complete switching among adult smokers in explaining its decision, providing a timely regulatory backdrop to the debate.
Sep.08
Altria’s USSTC Starts $250 Million Kentucky Expansion, Adding More Than 200 Jobs
Altria’s USSTC Starts $250 Million Kentucky Expansion, Adding More Than 200 Jobs
U.S. Smokeless Tobacco Company, an Altria Group company, has broken ground on an approximately $250 million manufacturing expansion in Hopkinsville, Kentucky. The roughly 270,000-square-foot facility is expected to create more than 200 jobs and absorb processing, manufacturing and packaging operations currently split between Hopkinsville and Nashville, Tennessee. USSTC previously said production at its Nashville facility is expected to wind down by early 2028. The project forms part of Altria’s broader effort to modernize and consolidate its U.S. smokeless tobacco manufacturing network.
Sep.10
Why AIRSCREAM Built its European Production Hub for Regulated Market Growth
Why AIRSCREAM Built its European Production Hub for Regulated Market Growth
AIRSCREAM’s production hub in the Czech Republic brings nicotine pouch manufacturing, e-liquid bottling, product documentation, warehousing and international logistics into one operation, giving brands and commercial partners a practical platform from which to launch, expand and enter new markets.
Market
Sep.16 by 2Firsts Perspectives
Product | PMI Launches ZYN Melts in UK, Extending ZYN Beyond Nicotine Pouches Into Dissolvable Tablets
Product | PMI Launches ZYN Melts in UK, Extending ZYN Beyond Nicotine Pouches Into Dissolvable Tablets
Philip Morris International (PMI) has launched ZYN Melts in the UK, introducing a fully dissolvable oral nicotine tablet format alongside the brand's existing nicotine pouches. The range includes Cool Mint and Peppermint, each offered at 1mg and 2mg of nicotine per tablet, creating four SKUs. Each can contains 20 tablets and is priced at £6.50 in the UK. Unlike ZYN nicotine pouches, Melts are placed between the upper lip and gum and dissolve completely during use.
News
Sep.29 by 2Firsts Perspectives